| Pharmacotherapy of acute coronary syndrome: the ACUITY trial. | |
| | |
MedLine Citation:
|
PMID: 19191676 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Bivalirudin, a direct thrombin inhibitor, has unique attributes including predictable pharmacokinetics, a reduction in bleeding complications and avoidance of heparin induced thrombocytopenia. OBJECTIVE: We critically review the role of bivalirudin in the management of patients with acute coronary syndrome in light of the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial. METHODS: Data from the ACUITY trial was critically reviewed along with other contemporary data. RESULTS/CONCLUSION: In the ACUITY trial, bivalirudin monotherapy was associated with rates of ischemic events that were noninferior to those associated with heparin plus glycoprotein IIb/IIIa inhibition, but was associated with a significantly reduced incidence of major bleeding. Bivalirudin seems to be an attractive antithrombotic agent in patients with acute coronary syndrome undergoing early invasive management. |
| | |
Authors:
|
Debabrata Mukherjee; Kim A Eagle |
Related Documents
:
|
10598366 - Aspirin, ticlopidine, and clopidogrel in acute coronary syndromes: underused treatments... 15800226 - Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. 21736726 - The relationship between inotrope exposure, six-hour postoperative physiological variab... 8542866 - Advances in antithrombotic drug therapy for coronary artery disease. 16423666 - Risk assessment in patients with depressed left ventricular function after myocardial i... 2880716 - Angina pectoris early after myocardial infarction: clinical experience of the multicent... |
Publication Detail:
|
Type: Comparative Study; Journal Article; Review |
Journal Detail:
|
Title: Expert opinion on pharmacotherapy Volume: 10 ISSN: 1744-7666 ISO Abbreviation: Expert Opin Pharmacother Publication Date: 2009 Feb |
Date Detail:
|
Created Date: 2009-02-04 Completed Date: 2009-05-20 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100897346 Medline TA: Expert Opin Pharmacother Country: England |
Other Details:
|
Languages: eng Pagination: 369-80 Citation Subset: IM |
Affiliation:
|
Division of Cardiovascular Medicine, Gill Heart Institute, University of Kentucky, 900 S. Limestone Street, 326 Wethington Building, Lexington, KY 40536-0200, USA. Mukherjee@uky.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Acute Coronary Syndrome
/
drug therapy*,
therapy Angioplasty, Transluminal, Percutaneous Coronary Anticoagulants / therapeutic use Drug Therapy, Combination Fibrinolytic Agents / adverse effects, therapeutic use* Heparin / therapeutic use Hirudins / adverse effects Humans Peptide Fragments / adverse effects, therapeutic use* Platelet Aggregation Inhibitors / therapeutic use Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors Randomized Controlled Trials as Topic Recombinant Proteins / adverse effects, therapeutic use Thrombin / antagonists & inhibitors* |
| Chemical | |
Reg. No./Substance:
|
0/Anticoagulants; 0/Fibrinolytic Agents; 0/Hirudins; 0/Peptide Fragments; 0/Platelet Aggregation Inhibitors; 0/Platelet Glycoprotein GPIIb-IIIa Complex; 0/Recombinant Proteins; 128270-60-0/bivalirudin; 9005-49-6/Heparin; EC 3.4.21.5/Thrombin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Pharmacotherapy of patients with schizophrenia and substance abuse.
Next Document: Tuberculosis pharmacotherapy: strategies to optimize patient care.